

(Rs. in lakhs)					
STATEMENT OF STANDALONE AUDITED RESULTS FOR THE YEAR ENDED 31st MARCH, 2016					
Particulars	3 months ended			Year ended	
	31.03.2016	31.12.2015	31.03.2015	31.03.2016	31.03.2015
	Unaudited			Audited	
1. Income from Operations					
(a) Net Sales/Income from Operations (Net of Excise Duty)	6,882	7,202	6,119	27,454	23,308
(b) Other Operating Income	148	115	557	478	919
Total Income from Operations (Net)	7,030	7,317	6,676	27,932	24,227
2. Expenses					
(a) Cost of Materials Consumed	1,309	1,611	1,222	6,025	5,920
(b) Purchases of Stock-in-Trade	960	741	505	3,360	2,378
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(25)	(74)	389	(241)	171
(d) Employee Benefits Expense	1,822	2,017	1,730	7,413	6,866
(e) Depreciation and Amortisation Expense	251	247	304	1,015	1,136
(f) Provision for Doubtful Debts and Advances (Net)	6	5	63	7	(323)
(g) Other Expenses	2,458	2,252	1,921	9,020	7,798
Total Expenses	6,781	6,799	6,134	26,599	23,946
3. Profit/(Loss) from Operations before Other Income, Finance Costs and Exceptional Items	249	518	542	1,333	281
4. Other Income	1	4	-	78	91
5. Profit/(Loss) from Ordinary Activities before Finance Costs	250	522	542	1,411	372
6. Finance Costs	25	55	72	249	272
7. Profit/(Loss) from Ordinary Activities before Tax	225	467	470	1,162	100
8. Tax Expense (including Deferred Tax)	-	-	-	-	-
9. Net Profit/(Loss) for the period	225	467	470	1,162	100
10. Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323	1,323
11. Reserves excluding Revaluation Reserves (as per last audited Balance Sheet)				12,036	11,193
12. Earnings/(Loss) per Share (of Rs. 8 each) (not annualised):					
(a) Basic	1.36	2.82	1.53	7.03	0.60
(b) Diluted	1.36	2.82	1.53	7.03	0.60

Notes:

1. Standalone Statement of Assets and Liabilities

Particulars	(Rs. in lakhs)	
	As at 31.3.2016	As at 31.3.2015
A EQUITY AND LIABILITIES		
1. Shareholders' Funds		
(a) Share Capital	1,323	1,323
(b) Reserves and Surplus	12,036	11,193
Sub-total - Shareholders' Funds	13,359	12,516
2. Non-Current Liabilities		
(a) Long-term Borrowings	24	32
(b) Deferred Tax Liabilities (Net)	-	-
(c) Other Long-term Liabilities	261	266
(d) Long-term Provisions	199	158
Sub-total - Non-Current Liabilities	484	456
3. Current Liabilities		
(a) Short-term Borrowings	2,196	3,246
(b) Trade Payables	3,371	2,530
(c) Other Current Liabilities	1,017	664
(d) Short-term Provisions	96	279
Sub-total - Current Liabilities	6,680	6,719
TOTAL - EQUITY AND LIABILITIES	20,523	19,691
B ASSETS		
1. Non-Current Assets		
(a) Fixed Assets	11,085	10,524
(b) Long-term Loans and Advances	719	557
Sub-total - Non-Current Assets	11,804	11,081
2. Current Assets		
(a) Inventories	3,902	3,448
(b) Trade Receivables	3,699	4,061
(c) Cash and Bank Balances	80	72
(d) Short-term Loans and Advances	1,038	1,029
Sub-total - Current Assets	8,719	8,610
TOTAL - ASSETS	20,523	19,691

2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its respective meetings held on 29th April, 2016.
3. The figures for the quarter ended 31st March, 2016 are the balancing figures between the audited financial results for the year ended 31st March, 2016 and the published unaudited financial results for the nine months ended 31st December, 2015.
4. The Company is exclusively engaged in the pharmaceuticals segment.
5. The Board of Directors at its meeting held on 14th March, 2016 had declared an interim dividend of Rs 1.60 per share of Rs 8/- each (20%) for the Financial year 2015-16 which was paid by the Company on 29th March 2016.
6. Figures for the prior periods have been regrouped where necessary.

For RPG Life Sciences Limited

CT. Renganathan
Managing Director
Mumbai, 29th April, 2016